These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 15572024)

  • 21. Matrix metalloproteinases generate angiostatin: effects on neovascularization.
    Cornelius LA; Nehring LC; Harding E; Bolanowski M; Welgus HG; Kobayashi DK; Pierce RA; Shapiro SD
    J Immunol; 1998 Dec; 161(12):6845-52. PubMed ID: 9862716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasminogen N-terminal activation peptide modulates the activity of angiostatin-related peptides on endothelial cell proliferation and migration.
    Hayashi M; Tamura Y; Dohmae N; Kojima S; Shimonaka M
    Biochem Biophys Res Commun; 2008 May; 369(2):635-40. PubMed ID: 18294956
    [TBL] [Abstract][Full Text] [Related]  

  • 23. No evidence for vasculogenesis regulation by angiostatin during mouse embryonic stem cell differentiation.
    Prandini MH; Desroches-Castan A; Feraud O; Vittet D
    J Cell Physiol; 2007 Oct; 213(1):27-35. PubMed ID: 17450519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutation of human plasminogen kringle 1-5 enhances anti-angiogenic action via increased interaction with integrin alpha(v)beta(3).
    Chang PC; Chang YJ; Wu HL; Chang CW; Lin CI; Wang WC; Shi GY
    Thromb Haemost; 2008 Apr; 99(4):729-38. PubMed ID: 18392331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasminogen kringle 5-engineered glioma cells block migration of tumor-associated macrophages and suppress tumor vascularization and progression.
    Perri SR; Nalbantoglu J; Annabi B; Koty Z; Lejeune L; François M; Di Falco MR; Béliveau R; Galipeau J
    Cancer Res; 2005 Sep; 65(18):8359-65. PubMed ID: 16166313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced expression of vascular endothelial growth factor paralleled with the increased angiostatin expression resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in human type 2 diabetic arterial vasculature.
    Chung AW; Hsiang YN; Matzke LA; McManus BM; van Breemen C; Okon EB
    Circ Res; 2006 Jul; 99(2):140-8. PubMed ID: 16778129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low dose adjuvant angiostatin decreases hepatic micrometastasis in murine ocular melanoma model.
    Yang H; Akor C; Dithmar S; Grossniklaus HE
    Mol Vis; 2004 Dec; 10():987-95. PubMed ID: 15623988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Arsenic trioxide (As2O3) inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-kappaB and reactive oxygen species.
    Park MJ; Lee JY; Kwak HJ; Park CM; Lee HC; Woo SH; Jin HO; Han CJ; An S; Lee SH; Chung HY; Park IC; Hong SI; Rhee CH
    J Cell Biochem; 2005 Aug; 95(5):955-69. PubMed ID: 15962302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Inhibitory effects of matrix metalloproteinase (MMP) inhibitor LY52 on expression of MMP-2 and MMP-9 and invasive ability of human ovarian carcinoma cell line SKOV3].
    Yuan YX; Xu WF; Liu J; Chen MH; Meng H; Qu XJ
    Ai Zheng; 2006 Jun; 25(6):663-70. PubMed ID: 16764758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiostatin binds ATP synthase on the surface of human endothelial cells.
    Moser TL; Stack MS; Asplin I; Enghild JJ; Højrup P; Everitt L; Hubchak S; Schnaper HW; Pizzo SV
    Proc Natl Acad Sci U S A; 1999 Mar; 96(6):2811-6. PubMed ID: 10077593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential production of angiostatin by concomitant antitumoral resistance-inducing cancer cells.
    Binda MM; Matar P; González AD; Rozados VR; Gervasoni SI; Scharovsky OG; Bonfil RD
    Int J Cancer; 2002 Jul; 100(1):14-21. PubMed ID: 12115581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Androgen receptor and invasion in prostate cancer.
    Hara T; Miyazaki H; Lee A; Tran CP; Reiter RE
    Cancer Res; 2008 Feb; 68(4):1128-35. PubMed ID: 18281488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel mechanism of IGF-binding protein-3 action on prostate cancer cells: inhibition of proliferation, adhesion, and motility.
    Massoner P; Colleselli D; Matscheski A; Pircher H; Geley S; Jansen Dürr P; Klocker H
    Endocr Relat Cancer; 2009 Sep; 16(3):795-808. PubMed ID: 19509068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Matrix metalloproteinase-19 inhibits growth of endothelial cells by generating angiostatin-like fragments from plasminogen.
    Brauer R; Beck IM; Roderfeld M; Roeb E; Sedlacek R
    BMC Biochem; 2011 Jul; 12():38. PubMed ID: 21787393
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasminogen derivatives encoding kringles 1-4 and kringles 1-5 exert indirect antiangiogenic and direct antitumoral effects in experimental lung cancer.
    Schmitz V; Raskopf E; Gonzalez-Carmona MA; Vogt A; Kornek M; Sauerbruch T; Caselmann WH
    Cancer Invest; 2008 Jun; 26(5):464-70. PubMed ID: 18568768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of human Angiostatin protein on human angiogenesis in vitro.
    Jung SP; Siegrist B; Wang YZ; Wade MR; Anthony CT; Hornick C; Woltering EA
    Angiogenesis; 2003; 6(3):233-40. PubMed ID: 15041799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of the VEGFR3/VEGFD receptor axis in TGFbeta1 activation of primary prostate cell lines.
    Goodyear SM; Kheyfets SB; Garcia FU; Stearns ME
    Prostate; 2009 Jun; 69(9):982-90. PubMed ID: 19301310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathological role of angiostatin in heart failure: an endogenous inhibitor of mesenchymal stem-cell activation.
    Yamahara K; Min KD; Tomoike H; Kangawa K; Kitamura S; Nagaya N
    Heart; 2009 Feb; 95(4):283-9. PubMed ID: 19095709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
    Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
    Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential binding of plasminogen, plasmin, and angiostatin4.5 to cell surface beta-actin: implications for cancer-mediated angiogenesis.
    Wang H; Doll JA; Jiang K; Cundiff DL; Czarnecki JS; Wilson M; Ridge KM; Soff GA
    Cancer Res; 2006 Jul; 66(14):7211-5. PubMed ID: 16849568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.